The CD4 marker, albeit expressed by a high percentage of leukemic cells at diagnosis (55–85% of AML cells, see Table 1), does not appear to specifically reflect residual disease, resulting in many false-positive results. This evidence concerns the gene CD4 and acute myeloid leukemia.